Andreas Greinacher, Germany

Vaccine induced thrombotic thrombocytopenia – Towards understanding the mechanisms

Andreas Greinacher, specialized for transfusion medicine, immunohematology and clinical immunology, is full professor and head of the department of transfusion medicine at the Universitätsmedizin Greifswald, Germany. His research interests are hereditary and immune mediated thrombocytopenias, especially heparin-induced thrombocytopenia and application of biophysics to understand molecular mechanisms of antigenicity of endogenous proteins. He has published more than 500 papers on these topics.

Kathleen Freson, Belgium

Inherited platelet disorders – Genomics

Kathleen Freson is Professor at the University of Leuven in the department of Cardiovascular Sciences and head of the Centre for Molecular and Vascular Biology. She has a background in bioscience engineering and her research focussed on genetic and biology studies using platelets to unravel new bleeding disorders but she studied also other mainly neurological diseases where the platelet was used as a model cell for the disease. She is Chair of the ISTH Subcommittee ‘Genomics in Thrombosis and Hemostasis’ and is a member of the NIH-funded ClinGen working group for Thrombosis and Hemostasis.

Pratima Chowdary, United Kingdom

Anti-tissue factor pathway inhibitor (TFPI) therapy in haemophilia

Pratima Chowdary is Professor of Haemophilia and Haemostasis, Dept. of Haematology, University College of London (UCL) and Centre Director for the Katharine Dormandy Haemophilia & Thrombosis Centre, Royal Free Hospital and. In addition, she serves as co-director for the National Haemophilia Database, run by United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO).

Her clinical interests include the care of patients with Haemophilia and related bleeding disorders. Her primary research interests include personalised management of Haemophilia, novel therapies in haemophilia including gene therapy, outcome assessments, haemophilic arthropathy and acquired coagulopathy. She is active in clinical trials and is the chief investigator for several non-interventional and interventional studies, including  UCL sponsored gene therapy studies.

She has authored several peer-reviewed publications and is a chair and member of various national and international working parties,  data safety monitoring boards, trial steering committees. She is a member of numerous professional societies, including the International Society on Thrombosis and Haemostasis, British Society of Haemostasis and Thrombosis, European Association of Allied Bleeding disorders and the World Federation of Haemophilia.

Cedric Hermans, Belgium

Haemophilia and gene therapy

Cedric Hermans currently heads the Division of Haematology, the Hemostasis and Thrombosis Unit as well as the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium. He was appointed Associate Professor at the Medical School of the Catholic University of Louvain in 2003, Full Professor in 2012 and Vice-Dean in 2015.

Professor Hermans has (co)-authored more than 85 original articles in international journals and is a member of several scientific societies and international advisory boards and collaborative research projects.

He was president of EAHAD and is currently member of the Board of Directors of the World Federation of Haemophilia and the Editor-in-Chief of the Haemophilia Journal.

His main research interests lie in the area of haemostasis and thrombosis, especially clinical studies on the treatment modalities and the wide spectrum of complications of haemophilia in both developed and developing countries, as well as new anticoagulants and the management of thrombosis.


Nick van Es, The Netherlands

Prediction of venous thromboembolism in cancer

Nick van Es is currently a fellow in Vascular Medicine at the Amsterdam University. He graduated cum laude as a Medical Doctor in 2012 and defended his PhD-thesis “Cancer and thrombosis: improvements in strategies for prediction, diagnosis, and treatment” cum laude in 2017 under supervision of Saskia Middeldorp and Patrick Bossuyt. During his PhD trajectory, he completed a research traineeship at the The Ottawa Hospital supervised by Marc Carrier and Phil Wells. Trained as a Clinical Epidemiologist, his current research focuses on prediction, diagnosis, and treatment of venous thromboembolism, with a particular interest in cancer-associate thrombosis. He has co-authored about 90 peer-reviewed publications and has established collaborations with various national and international experts in the field.

Viktoria Weber, Austria

Platelet-derived MVs and coagulation

Viktoria Weber obtained her PhD and her venia docendi for Biochemistry from the University of Natural Resources and Life Sciences in Vienna, Austria. She is Professor for Medical Biochemistry at Danube University Krems, were she leads the Department of Biomedical Research, and was head of the Christian Doppler Laboratory for Innovative Therapy Approaches in Sepsis (www.sepsisresearch.ac.at; 2013-2019).
She participated in several European projects in the field of apheresis, extracorporeal therapies, and sepsis. She is co-founder of the Austrian Society for Extracellular Vesicles (www.asev.at), Vice President of the Austrian Association of Molecular Life Sciences and Biotechnology (www.oegmbt.at) and President Elect of the European Society for Artificial Organs (www.esao.org). Her research focuses on the bloodbiomaterial interface, the activation of blood cells during blood-material contact, as well as extracellular vesicles (EVs) and their roles in coagulation and immunomodulation, particularly in the setting of inflammation. In this context, her group has set up a range of methods to characterize extracellular vesicles and their cellular origin directly in whole blood, which allows studying the interaction of EVs with blood cells without prior EV isolation.

Flora Peyvandi, Italy

The early response to an overwhelming epidemic, and the early treatment adaptations, e.g., with respect to thrombosis and anticoagulation

Flora Peyvandi is professor of Internal Medicine at the University of Milan, Italy and director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center at Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.

Dr. Peyvandi received her medical degree from the University of Milan, Italy and is certified in Haematology. She earned her PhD from the Maastricht University, The Netherlands for her research in the field of rare bleeding disorders. She was research fellow at the Royal Free Hospital, University College London, London, UK in 1997-98 for molecular characterisation of rare bleeding disorders and at the Veteran’s Administration Hospital, Harvard University, Boston, USA in 1998-99 for in vitro expression studies on novel gene variants in clotting disorders.

Dr. Peyvandi is dedicated to bringing state-of-the-art treatments and technologies to her research program and to offering patients the most novel therapeutic approaches available. Her research has been focused on the investigation of prevalence and mechanism of coagulation disorders and on the immunogenicity of coagulation products. She has participated for many years in educational and research activities of scientific societies and patients’ organizations, such as ISTH, EAHAD, WFH and EHC. She is currently president-elect of the International Society of Thrombosis and Haemostasis and president of the European Association for Haemophilia and Allied Disorders. She also serves on the Technical Health Committee of the Italian Ministry of Health.

Most recently, Dr. Peyvandi has focused on the management of hemostatic alterations in COVID-19 patients.

Peter Stenvinkel, Sweden

Biomimetic approaches in vascular disease

Peter Stenvinkel serves as a professor and senior lecturer at Dept. of Renal Medicine Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. He has published >590 original publications and reviews and 30 book chapters on various aspects of inflammation, wasting and metabolism in chronic kidney disease patients. His Hirsch index is 88 according to PubMed and 114 according to Google Scholar. He has given more than 400 invited lectures at various international meetings and congresses in about 30 different countries. He has received prize for the best Swedish thesis in diabetology 1994 and was a Baxter Extramural Grant awardee 1996. He was a Karolina Price awardee 2005 and a Vizenca price awardee 2009. He received the Addis Gold medal by the ISRNM for nutritional research 2010. He is a member of the council of International Society of Nephrology (2007-) and ERA-EDTA (2007-2010). He is an associate Editor of NDT and was editor-in-chief on NDT-E 2010-2013. He received an honorary membership of the Australian and New Zealand Society of Nephrology 2010 and of the Polish Society of Nephrology in 2012. He was an international NKF awardee 2012. He is a fellow of ERA-EDTA and ASN.

Register now for ECTH2021!